JP2020509016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509016A5 JP2020509016A5 JP2019546924A JP2019546924A JP2020509016A5 JP 2020509016 A5 JP2020509016 A5 JP 2020509016A5 JP 2019546924 A JP2019546924 A JP 2019546924A JP 2019546924 A JP2019546924 A JP 2019546924A JP 2020509016 A5 JP2020509016 A5 JP 2020509016A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide sequence
- composition according
- rna
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037923A JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
| JP2022203863A JP7461449B2 (ja) | 2017-02-28 | 2022-12-21 | 治療用ｒｎａ |
| JP2024045866A JP2024073650A (ja) | 2017-02-28 | 2024-03-22 | 治療用ｒｎａ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464981P | 2017-02-28 | 2017-02-28 | |
| US62/464,981 | 2017-02-28 | ||
| EP17306089.8 | 2017-08-23 | ||
| EP17306089 | 2017-08-23 | ||
| US201762597527P | 2017-12-12 | 2017-12-12 | |
| US62/597,527 | 2017-12-12 | ||
| PCT/US2018/019878 WO2018160540A1 (en) | 2017-02-28 | 2018-02-27 | Therapeutic rna |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037923A Division JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509016A JP2020509016A (ja) | 2020-03-26 |
| JP2020509016A5 true JP2020509016A5 (enExample) | 2021-07-29 |
| JP6949131B2 JP6949131B2 (ja) | 2021-10-13 |
Family
ID=61569463
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546924A Active JP6949131B2 (ja) | 2017-02-28 | 2018-02-27 | 治療用ｒｎａ |
| JP2021037923A Active JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
| JP2022203863A Active JP7461449B2 (ja) | 2017-02-28 | 2022-12-21 | 治療用ｒｎａ |
| JP2024045866A Pending JP2024073650A (ja) | 2017-02-28 | 2024-03-22 | 治療用ｒｎａ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037923A Active JP7201725B2 (ja) | 2017-02-28 | 2021-03-10 | 治療用ｒｎａ |
| JP2022203863A Active JP7461449B2 (ja) | 2017-02-28 | 2022-12-21 | 治療用ｒｎａ |
| JP2024045866A Pending JP2024073650A (ja) | 2017-02-28 | 2024-03-22 | 治療用ｒｎａ |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20200147176A1 (enExample) |
| EP (1) | EP3589308A1 (enExample) |
| JP (4) | JP6949131B2 (enExample) |
| KR (2) | KR102700956B1 (enExample) |
| CN (1) | CN110337305A (enExample) |
| AU (1) | AU2018229278A1 (enExample) |
| BR (1) | BR112019017743A2 (enExample) |
| CA (1) | CA3054733A1 (enExample) |
| CL (1) | CL2019002461A1 (enExample) |
| CO (1) | CO2019010355A2 (enExample) |
| CR (1) | CR20190444A (enExample) |
| EC (1) | ECSP19070336A (enExample) |
| IL (1) | IL268894A (enExample) |
| MA (1) | MA47680A (enExample) |
| MX (1) | MX2019010269A (enExample) |
| PE (1) | PE20200735A1 (enExample) |
| PH (1) | PH12019501959A1 (enExample) |
| SG (1) | SG11201907846VA (enExample) |
| TW (2) | TW202428301A (enExample) |
| UY (1) | UY37621A (enExample) |
| WO (1) | WO2018160540A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018160540A1 (en) * | 2017-02-28 | 2018-09-07 | Sanofi | Therapeutic rna |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
| CN113039277A (zh) | 2018-01-05 | 2021-06-25 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
| WO2020041655A1 (en) * | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| MX2021008434A (es) * | 2019-01-14 | 2021-09-23 | Genentech Inc | Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn. |
| TWI850316B (zh) * | 2019-01-21 | 2024-08-01 | 法商賽諾菲公司 | 用於晚期實性瘤癌症之治療性rna及抗pd1抗體 |
| WO2020154187A1 (en) * | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
| AU2020233995A1 (en) * | 2019-03-12 | 2021-09-23 | BioNTech SE | Therapeutic RNA for prostate cancer |
| WO2020200481A1 (en) * | 2019-04-05 | 2020-10-08 | Biontech Rna Pharmaceuticals Gmbh | Treatment involving interleukin-2 (il2) and interferon (ifn) |
| WO2021072172A1 (en) * | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| US20220380720A1 (en) * | 2019-11-12 | 2022-12-01 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| EP4096708A1 (en) * | 2020-01-31 | 2022-12-07 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
| US11547673B1 (en) * | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
| US20230295257A1 (en) | 2020-07-24 | 2023-09-21 | Strand Therapeutics Inc. | Lipid nanoparticle comprising modified nucleotides |
| KR102366490B1 (ko) * | 2020-10-20 | 2022-02-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| KR20230104140A (ko) * | 2020-11-04 | 2023-07-07 | 에트리스 게엠베하 | 바이러스 감염을 치료하기 위한 ifn-람다 mrna의 용도 |
| TW202245808A (zh) * | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| KR20230129479A (ko) | 2021-01-08 | 2023-09-08 | 스트랜드 세러퓨틱스 인코포레이티드 | 발현 구성체 및 이의 용도 |
| EP4087938A2 (en) * | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CN115702940A (zh) * | 2021-08-05 | 2023-02-17 | 苏州科锐迈德生物医药科技有限公司 | 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用 |
| WO2023056915A1 (en) * | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Polynucleotides encoding interleukin-12 (il-12) and related composition and methods thereof |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN116179549A (zh) | 2021-12-08 | 2023-05-30 | 南京吉迈生物技术有限公司 | 通过5’utr序列变体修饰基因转录和翻译效率 |
| IL316186A (en) | 2022-04-26 | 2024-12-01 | Strand Therapeutics Inc | Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof |
| CN115960906A (zh) * | 2022-05-07 | 2023-04-14 | 苏州科锐迈德生物医药科技有限公司 | 用于抗肿瘤免疫治疗的rna组合物、rna制剂及用途 |
| CN119013405A (zh) | 2022-05-13 | 2024-11-22 | 上海瑞宏迪医药有限公司 | 包含utr的核酸构建体及其应用 |
| CN117327709A (zh) * | 2022-06-24 | 2024-01-02 | 深圳瑞吉生物科技有限公司 | 用于实体肿瘤的治疗性mRNA及其应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| EP4561602A1 (en) | 2022-07-28 | 2025-06-04 | Stemcell Technologies Canada Inc. | Polynucleotides encoding linked antigens and uses thereof |
| WO2024074211A1 (en) * | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| IL319682A (en) * | 2022-10-06 | 2025-05-01 | BioNTech SE | RNA complexes targeting claudin-18.2 |
| WO2024216162A1 (en) | 2023-04-12 | 2024-10-17 | Strand Therapeutics Inc. | Synthetic circuits and uses thereof |
| AU2024299528A1 (en) | 2023-07-24 | 2026-03-12 | Strand Therapeutics Inc. | Rna-based synthetic circuit for producing engineered immune cells for an extracorporeal cell therapy |
| AU2024299882A1 (en) | 2023-07-25 | 2026-01-08 | Strand Therapeutics Inc. | Polynucleotides comprising a micro rna detargeting sensor and uses thereof |
| KR102935773B1 (ko) * | 2023-09-01 | 2026-03-09 | 한양대학교 산학협력단 | 증강된 유전자 발현을 위한 5‘ 비번역 영역을 포함하는 뉴클레오타이드를 포함하는 조성물 및 방법 |
| WO2025217591A1 (en) | 2024-04-12 | 2025-10-16 | Strand Therapeutics Inc. | Human-derived synthetic regulators and uses thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP1442750B1 (en) | 1997-11-20 | 2012-08-01 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
| EP1248654B1 (en) | 2000-01-20 | 2005-10-05 | Universität Zürich Institut für Medizinische Virologie | Intra-tumoral administration of il-12 encoding naked nucleic acid molecules |
| ES2164011B1 (es) | 2000-02-25 | 2003-05-16 | Inst Cientifico Tecnol Navarra | Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos. |
| EP2842964A1 (de) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20130108663A1 (en) | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| ES2573458T3 (es) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| CA2710534C (en) | 2008-01-31 | 2018-09-04 | Curevac Gmbh | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
| WO2009114816A2 (en) | 2008-03-14 | 2009-09-17 | The Board Of Trustees Of The University Of Illinois | Therapeutic cancer antigens |
| WO2009149539A1 (en) | 2008-06-10 | 2009-12-17 | Université de Montréal | Enhancing antigen-specific cd8+ t cell response using irf-7 mrna |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| SI3112467T1 (en) | 2009-12-07 | 2018-06-29 | The Trustees Of The University Of Pennsylvania | Rna preparations comprising purified modified rna for reprogramming cells |
| CN103038343A (zh) | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| DK2590676T3 (en) | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| DK4108671T3 (da) | 2010-10-01 | 2025-01-06 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| JP6113737B2 (ja) | 2011-10-03 | 2017-04-12 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法 |
| US20150017121A1 (en) | 2011-10-11 | 2015-01-15 | Universitat Zurich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| EP2834259A4 (en) * | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| EP2911684B1 (en) * | 2012-10-24 | 2019-06-19 | Novartis Ag | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| CN105073135A (zh) | 2013-02-22 | 2015-11-18 | 库瑞瓦格有限责任公司 | 疫苗接种和抑制pd-1途径的组合 |
| CA2904151C (en) * | 2013-03-14 | 2023-09-12 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| MX2016002153A (es) | 2013-08-21 | 2017-03-01 | Curevac Ag | Composicion y vacuna para tratar cancer de prostata. |
| SG11201510748PA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| SG11201604781RA (en) | 2013-12-18 | 2016-07-28 | Intrexon Corp | Single chain il-12 nucleic acids, polypeptids, and uses thereof |
| GB2517521B (en) | 2013-12-19 | 2015-07-29 | Anacail Ltd | Drain decontamination system |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| CN105031630A (zh) * | 2014-04-28 | 2015-11-11 | 四川大学 | 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法 |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
| EP3289083A4 (en) | 2015-04-27 | 2018-12-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| HUE055207T2 (hu) | 2015-07-30 | 2021-11-29 | Macrogenics Inc | PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017027843A1 (en) * | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| US11723932B2 (en) | 2016-01-11 | 2023-08-15 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| EP3500295A2 (en) | 2016-08-19 | 2019-06-26 | CureVac AG | Rna for cancer therapy |
| WO2018160540A1 (en) | 2017-02-28 | 2018-09-07 | Sanofi | Therapeutic rna |
| WO2020041655A1 (en) | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| TWI850316B (zh) | 2019-01-21 | 2024-08-01 | 法商賽諾菲公司 | 用於晚期實性瘤癌症之治療性rna及抗pd1抗體 |
| WO2020154187A1 (en) | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
-
2018
- 2018-02-27 WO PCT/US2018/019878 patent/WO2018160540A1/en not_active Ceased
- 2018-02-27 PE PE2019001764A patent/PE20200735A1/es unknown
- 2018-02-27 MA MA047680A patent/MA47680A/fr unknown
- 2018-02-27 AU AU2018229278A patent/AU2018229278A1/en not_active Abandoned
- 2018-02-27 JP JP2019546924A patent/JP6949131B2/ja active Active
- 2018-02-27 TW TW112135033A patent/TW202428301A/zh unknown
- 2018-02-27 KR KR1020197028213A patent/KR102700956B1/ko active Active
- 2018-02-27 BR BR112019017743A patent/BR112019017743A2/pt not_active IP Right Cessation
- 2018-02-27 UY UY0001037621A patent/UY37621A/es not_active Application Discontinuation
- 2018-02-27 EP EP18709243.2A patent/EP3589308A1/en active Pending
- 2018-02-27 CN CN201880013857.3A patent/CN110337305A/zh active Pending
- 2018-02-27 KR KR1020247028726A patent/KR20240144261A/ko active Pending
- 2018-02-27 MX MX2019010269A patent/MX2019010269A/es unknown
- 2018-02-27 TW TW107106479A patent/TW201842921A/zh unknown
- 2018-02-27 CR CR20190444A patent/CR20190444A/es unknown
- 2018-02-27 SG SG11201907846VA patent/SG11201907846VA/en unknown
- 2018-02-27 CA CA3054733A patent/CA3054733A1/en active Pending
-
2019
- 2019-08-25 IL IL26889419A patent/IL268894A/en unknown
- 2019-08-26 CL CL2019002461A patent/CL2019002461A1/es unknown
- 2019-08-27 PH PH12019501959A patent/PH12019501959A1/en unknown
- 2019-08-27 US US16/552,248 patent/US20200147176A1/en not_active Abandoned
- 2019-09-25 CO CONC2019/0010355A patent/CO2019010355A2/es unknown
- 2019-09-27 EC ECSENADI201970336A patent/ECSP19070336A/es unknown
-
2021
- 2021-03-10 JP JP2021037923A patent/JP7201725B2/ja active Active
- 2021-04-30 US US17/245,605 patent/US11865159B2/en active Active
-
2022
- 2022-12-21 JP JP2022203863A patent/JP7461449B2/ja active Active
-
2023
- 2023-11-21 US US18/516,006 patent/US20240173382A1/en active Pending
-
2024
- 2024-03-22 JP JP2024045866A patent/JP2024073650A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020509016A5 (enExample) | ||
| AU2017374044B2 (en) | Modified guide RNAs | |
| Green et al. | Sequence analysis of the gene encoding the serotype-specific glycoprotein (VP7) of two new human rotavirus serotypes | |
| EP4527459A3 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
| ZA202003137B (en) | Nucleic acid, composition and conjugate containing same, and preparation method and use | |
| JP2014525461A5 (enExample) | ||
| JP2020022459A5 (enExample) | ||
| JP2013535212A5 (enExample) | ||
| JP2015128433A5 (enExample) | ||
| ATE386127T1 (de) | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie | |
| RU2016109938A (ru) | Композиция и вакцина для лечения рака предстательной железы | |
| JP2018512110A5 (enExample) | ||
| JP2015513897A5 (enExample) | ||
| JP2017070307A5 (enExample) | ||
| EP3233113A1 (en) | Ebolavirus and marburgvirus vaccines | |
| JP2014527401A5 (enExample) | ||
| JP2005500025A5 (enExample) | ||
| JP2009544281A5 (enExample) | ||
| EP2527445A3 (en) | Treatment and prevention of influenza | |
| JP2011524745A5 (enExample) | ||
| Sinnuengnong et al. | Administration of co-expressed Penaeus stylirostris densovirus-like particles and dsRNA-YHV-Pro provide protection against yellow head virus in shrimp | |
| WO2002044390A3 (en) | Floral development genes | |
| JP2022078067A5 (enExample) | ||
| NZ604094A (en) | Double stranded rna compounds to rhoa and use thereof | |
| WO2004018630A3 (en) | Recombinant double-stranded rna phages and uses thereof |